BACKGROUND: Vascular calcification is associated with mortality and cardiovascular events in patients with chronic kidney disease. AST-120, which adsorbs uremic toxins, is reported to reduce the risk of cardiovascular disease and death in chronic kidney disease patients. The aim of the current study was to investigate the association between abdominal aortic calcification and the use of AST-120 in predialysis chronic kidney disease patients. METHODS: A retrospective analysis was conducted including 199 predialysis chronic kidney disease patients (stages 4 and 5) who underwent abdominal plain computed tomography in our institution between 2005 and 2010. Abdominal aortic calcification was assessed by aortic calcification index (ACI). Patients were divided into two groups based on whether or not AST-120 was administered for at least six months, and ACI was compared between the two groups. RESULTS: The aortic calcification index was significantly lower in patients taking AST-120 [12.2 (2.5-30.3) vs. 25.7 (13.4-45.3) %, P < 0.001]. According to multivariate linear regression analysis, the use of AST-120 was independently and significantly correlated with ACI after adjusting for confounding factors. CONCLUSIONS: The use of AST-120 was independently associated with less aortic calcification in predialysis chronic kidney disease patients.
BACKGROUND:Vascular calcification is associated with mortality and cardiovascular events in patients with chronic kidney disease. AST-120, which adsorbs uremic toxins, is reported to reduce the risk of cardiovascular disease and death in chronic kidney diseasepatients. The aim of the current study was to investigate the association between abdominal aortic calcification and the use of AST-120 in predialysis chronic kidney diseasepatients. METHODS: A retrospective analysis was conducted including 199 predialysis chronic kidney diseasepatients (stages 4 and 5) who underwent abdominal plain computed tomography in our institution between 2005 and 2010. Abdominal aortic calcification was assessed by aortic calcification index (ACI). Patients were divided into two groups based on whether or not AST-120 was administered for at least six months, and ACI was compared between the two groups. RESULTS: The aortic calcification index was significantly lower in patients taking AST-120 [12.2 (2.5-30.3) vs. 25.7 (13.4-45.3) %, P < 0.001]. According to multivariate linear regression analysis, the use of AST-120 was independently and significantly correlated with ACI after adjusting for confounding factors. CONCLUSIONS: The use of AST-120 was independently associated with less aortic calcification in predialysis chronic kidney diseasepatients.
Authors: Fellype C Barreto; Daniela V Barreto; Sophie Liabeuf; Natalie Meert; Griet Glorieux; Mohammed Temmar; Gabriel Choukroun; Raymond Vanholder; Ziad A Massy Journal: Clin J Am Soc Nephrol Date: 2009-08-20 Impact factor: 8.237
Authors: Ran-Hui Cha; Shin Wook Kang; Cheol Whee Park; Dae Ryong Cha; Ki Young Na; Sung Gyun Kim; Sun Ae Yoon; Sejoong Kim; Sang Youb Han; Jung Hwan Park; Jae Hyun Chang; Chun Soo Lim; Yon Su Kim Journal: Kidney Res Clin Pract Date: 2017-03-31